Immunicom

"Company praised for efforts to create affordable and effective novel cancer immunotherapies and promising technology platform with broad potential to develop a multitude of products." Read more on why Immunicom is recognized as one of the Most Promising Biotech Startups of 2020, http://ow.ly/k56450DhXou.

"We found that a large group of proteins - cytokines - which traditionally regulate the immune system are also used by the disease-causing agents to defend against the immune system," said Amir Jafri, Immunicom, CEO. Read more about Immunicom's investigational immunotherapy treatment: http://ow.ly/310Q50CSwPB

"Immunotherapy for stomach cancer may work better if the therapy is delivered earlier in the course of disease and in combination with standard chemotherapy." Source Technology Networks: http://ow.ly/6ppW50CSwBN

"Designed to address different types of solid tumors, the LW-02 Immunopheresis column is going through multiple trials for various cancers across Europe." Read about Immunicom's oncology trials for multiple cancers, including #TNBC, #NSCLC, metastatic melanoma and renal cell carcinoma. http://ow.ly/JDiX50CSwpC

New immune cell findings from the Pritzker School of Molecular Engineering could lead to more effective #vaccines for existing and novel viruses. Source Genetic Engineering & Biotechnology News: http://ow.ly/x08150CSw72